Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

docetaxel/ritonavir

An orally bioavailable combination agent containing docetaxel, a second generation taxane, and ritonavir, a cytochrome P450 (CYP) 3A4 inhibitor, with potential enhanced antineoplastic activity. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death. Docetaxel is metabolized by CYP3A4 enzymes which is inhibited by the presence of ritonavir. This increases the plasma concentration of docetaxel and may increase docetaxel’s efficacy.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	ModraDoc006/r oral docetaxel/ritonavir

docetaxel/ritonavir

Search NCI's Drug Dictionary